MM.1S: A model for multiple myeloma

It is estimated that in 2017 there will be about 30,000 new cases diagnosed and about 13,000 patient deaths from multiple myeloma. However, it is a relatively uncommon type of cancer with a lifetime risk of 1 in 143 (0.7%). The risk of being diagnosed with multiple myeloma increases as people age, with the majority of people being diagnosed at age 65 or older. Men are slightly more likely to develop multiple myeloma than women and African Americans are twice as likely to develop this type of cancer. However, the greatest risk factor for begin diagnosed with multiple myeloma is already having a plasma cell disease. Patients with monoclonal gammopathy of undetermined significance (MGUS) or solitary plasmacytoma will eventually develop multiple myeloma.

Modeling liver cancer with syngeneic hepa 1-6: an update

Hepatocellular carcinoma (HCC) affects over one million people globally and is currently the third leading cause of cancer related deaths in the world.[1] Worldwide, there are 800,000 new diagnoses and 700,000 patient deaths each year. The incidence of HCC is highest in Southeast Asia and Sub-Saharan Africa due to high prevalence of hepatitis B and C viruses which strongly predisposes one to develop chronic liver disease and subsequent HCC.[1,2]  In the United States, there are expected to be 42,030 new diagnoses and 31,780 patient deaths in 2019.[2]

CT26: Murine colon carcinoma

Preclinically, the murine CT26 colon carcinoma line has become a platform model for evaluating the potential of drug combinations with immune checkpoint inhibitor antibodies. It is a highly immunogenic tumor and tends to show objective response rates to a number of commercially available checkpoint inhibitors. At Labcorp, we have run this model more than a dozen times in the past nine months, with additional studies being scheduled regularly.

Hepa 1-6: A murine model of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is an aggressive malignancy which has gradually increased in incidence to affect one million people worldwide and is currently the third leading cause of cancer related deaths in the world.[1,2] The prevalence of HCC is highest in Asia and Africa due to high endemicity of hepatitis B and C viruses which strongly predispose to the development of chronic liver disease and subsequent HCC.[1] 

Pan02: A murine model of pancreatic cancer

Pancreatic cancer is the ninth most commonly diagnosed cancer and ranks as one of the deadliest with the lowest 5-year survival rate of 5-8%.[1,2,3] This year alone, the American Cancer Society estimates that 56,770 people will be diagnosed with the disease of which more than 45,750 people may not survive. Pancreatic ductal adenocarcinoma (PDAC) being the most prevalent and aggressive form of exocrine pancreatic cancer accounts for ~90% of cases with mortality equaling incidence.[4,5]

Modeling human acute lymphoblastic leukemia (ALL) – using the NALM6-Luc-mCh-Puro model for the development of CAR T cell therapies

Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid lineage characterized by the development of increased numbers of immature lymphocytes. ALL is a relatively rare cancer, representing less than 0.5% of all cancers in the United States, with the American Cancer Society estimating approximately 5,930 new cases and 1,500 deaths from ALL in the United States for 2019. However, the fact that ALL is the most common childhood cancer makes it of interest to researchers. The risk for developing ALL is highest in children younger than 5 years of age. This risk then declines slowly until the mid-20s before it begins to rise again after age 50. While most cases of ALL occur in children, most deaths from ALL occur in adults. Standard therapies for ALL include the use of aggressive or long-term chemotherapy. These treatment regimens result in 90% of children surviving after five years. However, this drops to around 40% of adult patients remaining disease free. Due to this relapse rate in ALL, other treatment options have been sought.

C1498: A murine model for acute myelogenous leukemia (AML)

Acute myelogenous leukemia (AML) is a rapidly progressing malignancy of myeloid white blood cells.  An estimated 21,380 new cases of AML and 10,590 deaths will occur in the United States in 2017. AML results from excessive proliferation of dedifferentiated or undifferentiated myeloid leukocytes initially in the bone marrow. As disease progresses, AML blast cells will be found in the blood and other secondary lymphoid organs. Symptoms including anemia and leukopenia result from proliferating AML cells suppressing normal hematopoiesis in the bone marrow. AML is characterized by a complex number of subtypes that are defined by genomic alterations and gene expression profiling. Treatment typically starts with intensive chemotherapy followed by allogeneic bone marrow transplantation (BMT) in patients that can tolerate these therapies. Less debilitating treatment options, including immunotherapy, are needed for older AML patients who frequently cannot tolerate intensive chemotherapy or BMT.

A New Labcorp Offering: Predictive Oncology® Reconstructed Bone (r-Bone), plate-based, 3-dimensional (3D) culture assay that mimics the tumor microenvironment found in myeloma, acute myelogenous leukemia and solid tumor metastasis.

In order to provide a more reflective model of how tumor cells would respond to test agents in vivo, the tissue physiology where the tumor grows and proliferates needs to be recapitulated in vitro. This process has been accomplished using Predictive Oncology® organ-specific three-dimensional (3D) matrices that support long-term culture of carcinoma cells. Labcorp and Predictive Oncology® have worked together to develop tumor-specific 3D models, based on Predictive Oncology® proprietary 3D cell culture platform for preclinical testing and research studies in the biopharmaceutical industry. This tech spotlight highlights the characteristics of the Reconstructed Bone (r-Bone) model.

B16-F10: a murine melanoma model

Skin cancers include carcinomas of all layers of the skin with the most common being basal cell (BCC) and squamous cell carcinomas (SCC). Melanoma and non-melanoma skin cancers (Merkel cell carcinoma, Kaposi sarcoma, cutaneous lymphoma and other sarcomas) are much less common.  Of all the skin cancer types, melanoma is a serious form of skin cancer that begins in melanocytes, the melanin-producing neural crest-derived cells located in the bottom layer (the stratum basale) of the skin’s epidermis. While malignant BCC and SCC are rarely metastatic, the less common malignant melanoma, on the other hand, is highly aggressive and spreads rapidly to other parts of the body. Melanomas present in many different shapes, sizes and colors with a comprehensive set of warning signs.[1] 

Absolute counts by flow cytometry — maximize the accuracy of your immunophenotypic data interpretation

In this Tech Spotlight we will present the principles of absolute counting and the advantages this service provides when used in combination with tumor immunophenotypic analysis.